InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,717.28
(
1.76%
)
US TECH 100
19,440.80
(
3.09%
)
Dow Jones
42,023.74
(
1.25%
)
Brent Oil
74.26
(
2.59%
)
Bitcoin
63,565.06
(
3.07%
)
Post# of 30001
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

$Pistol Pete$

Send PM Follow Ignore
Followers 2540
Posts 250759
Boards Moderated 35
Alias Born 05/06/2014

$Pistol Pete$

Re: None

Sunday, 06/17/2018 6:52:09 PM

Sunday, June 17, 2018 6:52:09 PM

Post# of 30001
$MNKD “We are pleased to have completed the TreT Phase 1 trial, which met the study’s safety, tolerability and pharmacokinetics objectives,” stated David Kendall, Chief Medical Officer of MannKind. “We are excited to utilize our existing technology platform and device capabilities to create an easy-to-use and tolerable formulation of treprostinil to help unmet patient needs in a serious chronic disease such as PAH.”

https://www.streetinsider.com/Corporate+News/MannKind+%28MNKD%29+Completes+Phase+1+Trial+of+Treprostinil+Technosphere+for+PAH+Advancing+Development+to+Next+Phase/14283663.html


investorshub.advfn.com/$Pistol-Pete$-$Mick$-&-Friends-Stock-Picks-29568/

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up